Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
Rapid AML Therapeutic Panel
- Molecular
The Rapid AML Therapeutic Panel was designed to assess key biomarkers associated with acute myeloid leukemia (AML). It includes the following testing methodologies and markers:
Sanger Sequencing:
TP53
PCR/Fragment Analysis:
FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA
FISH Probes:
5q-, -5 (5p15, 5q31, 5q33)
7q-, -7 (Cen 7, 7q22, 7q31)
RUNX1/RUNX1T1 (ETO/AML1) t(8;21)
MLL (11q23)
PML/RARA t(15;17)
CBFB inv(16), t(16;16)
17p- (TP53 17p13.1, NF1 17q11.2)
Test reports include a summary of all results together.
Specimen Requirements
Bone Marrow Aspirate: 2-3 mL in sodium heparin tube. EDTA is acceptable.
Peripheral Blood: 5 mL in sodium heparin tube. EDTA is acceptable.
Fluids: Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.
CPT Code(s)*
Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive Myeloid Disorders, or one of the NeoTYPE Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: August 05, 2025